We are live on ! Find out more
SIP

Stoneridge Investment Partners Portfolio holdings

AUM $152M
1-Year Est. Return 20.58%
This Fund
S&P 500
This Quarter Est. Return
+1.31%
1 Year Est. Return
+20.58%
3 Year Est. Return
+44.17%
5 Year Est. Return
+32.14%
10 Year Est. Return
+92.72%
AUM
$636M
AUM Growth
-$35.2M
Cap. Flow
-$41.5M
Cap. Flow %
-6.53%
Top 10 Hldgs %
23.23%
Holding
318
New
67
Increased
31
Reduced
120
Closed
80

Top Buys

Rank Stock Value
1
MO icon
Altria Group
MO
+$12.2M
2
MDLZ icon
Mondelez International
MDLZ
+$10.9M
3
NWL icon
Newell Brands
NWL
+$9.58M
4
MRK icon
Merck
MRK
+$9.37M
5
WY icon
Weyerhaeuser
WY
+$7.26M

Sector Composition

Rank Sector Weight
1 Financials 19.76%
2 Technology 12.98%
3 Healthcare 12.94%
4 Consumer Staples 11.54%
5 Communication Services 10.51%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
VSTM icon
226
Verastem
VSTM
$610M
$129K 0.02%
2,293
ATEN icon
227
A10 Networks
ATEN
$1.95B
$109K 0.02%
+14,479
New +$98.6K
TTI icon
228
TETRA Technologies
TTI
$1.26B
$94K 0.01%
32,765
-14,774
-31% -$36.2K
DRRX
229
DELISTED
DURECT Corp
DRRX
$65K 0.01%
3,695
FTK icon
230
Flotek Industries
FTK
$1.28B
$60K 0.01%
2,158
+483
+29% +$19.1K
MGNI icon
231
Magnite
MGNI
$3.55B
$56K 0.01%
14,444
HIVE
232
DELISTED
Aerohive Networks
HIVE
$53K 0.01%
12,848
+2,135
+20% +$8.56K
AT
233
DELISTED
Atlantic Power Corporation
AT
$50K 0.01%
20,342
ARQL
234
DELISTED
Arqule Inc
ARQL
$38K 0.01%
34,268
CLDX icon
235
Celldex Therapeutics
CLDX
$3.28B
$37K 0.01%
864
ECYT
236
DELISTED
Endocyte, Inc. Common Stock
ECYT
$26K ﹤0.01%
18,684
TPST icon
237
Tempest Therapeutics
TPST
$14.6M
$16K ﹤0.01%
4
NBSE
238
DELISTED
NeuBase Therapeutics, Inc. Common Stock
NBSE
$11K ﹤0.01%
37
AAL icon
239
American Airlines Group
AAL
$10.6B
-57,467
Closed -$2.89M
AFL icon
240
Aflac
AFL
$62.6B
-105,954
Closed -$4.12M
AME icon
241
Ametek
AME
$58.2B
-30,732
Closed -$1.86M
AMT icon
242
American Tower
AMT
$80.4B
-22,932
Closed -$3.03M
AVY icon
243
Avery Dennison
AVY
$13.4B
-4,270
Closed -$377K
AXTA icon
244
Axalta
AXTA
$8.17B
-12,753
Closed -$409K
BCC icon
245
Boise Cascade
BCC
$3.02B
-10,064
Closed -$306K
BGS icon
246
B&G Foods
BGS
$286M
-6,029
Closed -$215K
BRO icon
247
Brown & Brown
BRO
$23.9B
-30,882
Closed -$665K
CF icon
248
CF Industries
CF
$17.3B
-126,850
Closed -$3.55M
CHRW icon
249
C.H. Robinson
CHRW
$17.5B
-56,401
Closed -$3.87M
CHTR icon
250
Charter Communications
CHTR
$18.2B
-26,419
Closed -$8.9M

Similar funds

Stoneridge Investment Partners's Q3 2017 Portfolio in Review

As of Q3 2017, Stoneridge Investment Partners held 318 positions worth $636M, down 5.2% from $671M the previous quarter. Its ten largest holdings account for 23% of the portfolio.

Stoneridge Investment Partners withdrew a net $41.5M in Q3 2017, closing 80 positions and reducing 120 holdings. Its most notable exit was Gilead Sciences, an estimated $20M position sold in full.

By sector, the portfolio is most concentrated in Financials at 20% of assets, up from 19% a quarter earlier, followed by Technology and Healthcare.

Against the trend, Stoneridge Investment Partners opened a new position in Altria Group worth $11.6M.

  • Stoneridge Investment Partners's largest Q3 2017 buy was Altria Group: 183,060 shares worth $11.6M.
  • Stoneridge Investment Partners added most to Apple in Q3 2017, an estimated $4.06M increase.
  • Stoneridge Investment Partners's biggest Q3 2017 reduction was Tyson Foods, cutting an estimated $7.78M.
  • Stoneridge Investment Partners fully exited Gilead Sciences in Q3 2017, selling an estimated $20M.
  • Stoneridge Investment Partners's ten largest holdings make up 23% of its $636M portfolio in Q3 2017.
  • Stoneridge Investment Partners opened 67 new positions and closed 80 in Q3 2017.
  • Stoneridge Investment Partners's portfolio value fell 5.2% quarter-over-quarter to $636M.

Based on Stoneridge Investment Partners's 13F filing for Q3 2017, filed 2 Nov 2017.